Company Overview
Snapshot
Founded in April 2021 by Dr. Eitan, Gary Binyamin, Tanhum Feld, and Eran Vickus, Slate Therapeutics operates with 1–10 employees. The company has raised $1M across one funding round from 2 investors. In January 2022, Slate Therapeutics secured pre-seed funding from NGT HealthCare II.
Business overview
Slate Therapeutics is a Health Tech & Life Sciences company focused on revolutionizing the treatment of chronic rhinosinusitis (CRS). The company's core product, SilexGel, is a novel sol-gel hydrogel technology designed for the systemic and localized delivery of therapeutics. This platform aims to provide long-lasting effects with minimal side effects, addressing limitations of existing treatments like drug-eluting implants and nasal sprays. Slate Therapeutics operates within the Pharma & Medical Biotechnology sector, specifically in Drug Delivery and Drugs Discovery & Development, targeting the Healthcare & Life Sciences industry and patients.
Log in to access full profile ›Company Intelligence Q&A
- What is Slate Therapeutics' primary focus?
- Slate Therapeutics is dedicated to revolutionizing the treatment of chronic rhinosinusitis (CRS) using its novel SilexGel technology.
- What is SilexGel?
- SilexGel is a cutting-edge sol-gel hydrogel platform technology developed by Slate Therapeutics for the systemic and localized delivery of therapeutics, designed to offer long-lasting effects with minimal side effects.
- When was Slate Therapeutics founded?
- Slate Therapeutics was founded in April 2021.
- Who are the founders of Slate Therapeutics?
- The company was founded by Dr. Eitan, Gary Binyamin, Tanhum Feld, and Eran Vickus.
- What was a significant early funding event for Slate Therapeutics?
- In January 2022, Slate Therapeutics secured pre-seed funding from NGT HealthCare II and Israel Innovation Authority.